期刊
BIOTECHNOLOGY ADVANCES
卷 19, 期 6, 页码 435-450出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0734-9750(01)00065-9
关键词
radioimmunotherapy; monoclonal antibody; cancer; pretargeting; pharmacokinetics; peptides; drug targeting; indium-111; yttrium-90; polyethyleneglycol (PEG)
A major focus of current drug research is to improve drug targeting to internal target sites such as to solid tumors or specific organs. The objective of drug targeting, especially for cancer chemotherapy and radioimmunotherapy, is to enhance the effectiveness of the drug by concentrating it at the target site and minimizing its effects in nontarget sites. Although tumor targeting has been obtained with large long-circulating radiolabeled antibody molecules, normal organ activity, especially in the blood kidneys, liver, and bone marrow is a significant problem. Over the last 20 years, studies to improve the therapeutic use of antibodies have included the use of antibody fragments, chase molecules, metabolizable linkers, antibody-directed enzyme prodrugs (ADEPT), local delivery, and pretargeting. Here, we will review the most interesting recent advances in pretargeting biotechnology. (C) 2001 Elsevier Science Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据